Trial Profile

Adebrelimab Plus Albumin-bound Paclitaxel, Carboplatin and Recaticimab Perioperative Treatment for Resectable NSCLC, a Phase II Clinical Study

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adebrelimab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary) ; Recaticimab (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use

Most Recent Events

16 Dec 2024 The protocol has been amended to change in Arms and Interventions for dose frequency of recaticimab (150 mg, SC, D1,from Q4W to Q3W).
16 Dec 2024 Planned End Date changed from 1 Dec 2026 to 1 Mar 2027.
16 Dec 2024 Planned primary completion date changed from 1 Dec 2025 to 1 Aug 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com